BCG Vaccine Market (2026 - 2033)

BCG Vaccine Market Summary

The global BCG vaccine market size was valued at USD 181.8 million in 2025 and is projected to grow from USD 190.3 million in 2026 to USD 275.5 million by 2033, at a CAGR of 5.4% from 2026 to 2033. Asia Pacific dominated the market, accounting for the largest share of 47.8% in 2025. The industry is supported by the continued use of the Bacillus Calmette-Guérin (BCG) vaccine for tuberculosis (TB) prevention and the treatment of non-muscle invasive bladder cancer.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The vaccine is included in national immunization programs in many countries with a moderate to high TB burden, especially across Asia Pacific, Africa, and parts of Latin America. Government vaccination programs and procurement by public health agencies continue to support market demand. The market has a limited number of manufacturers, making supply dependent on production capacity, regulatory compliance, and quality standards. Manufacturers are investing in production upgrades and capacity expansion to improve product availability. Research on new therapeutic uses of BCG is ongoing, but its primary use remains TB prevention and bladder cancer treatment. Support from global health organizations, continued focus on tuberculosis control, and stable demand from public healthcare systems continue to maintain the market across developed and developing countries.

To learn more about this report, Download Free Sample Report

Market Dynamics

Market Concentration & Characteristics

The degree of innovation is moderate in the BCG vaccine industry. Most research is focused on improving manufacturing processes, increasing production capacity, and evaluating BCG in combination with immunotherapies for bladder cancer. The vaccine itself has remained largely unchanged for tuberculosis prevention, with manufacturers concentrating on product quality, supply stability, and process improvements rather than introducing new vaccine formulations.

The barriers to entry are high in this industry because manufacturing the BCG vaccine requires specialized biological production facilities, skilled technical expertise, and compliance with strict regulatory and quality standards. New manufacturers must complete detailed validation processes and obtain approvals from regulatory authorities before commercial production, making market entry both time-consuming and capital-intensive.

To learn more about this report, Download Free Sample Report

The impact of regulations is high in the industry. Manufacturers must comply with national regulatory requirements, Good Manufacturing Practices (GMP), and World Health Organization guidelines to ensure product quality, safety, and consistency. Regular inspections, quality testing, and batch release requirements directly affect production timelines and vaccine supply.

The availability of product substitutes is low because BCG remains the only widely used vaccine for routine tuberculosis prevention in newborns and infants in countries where vaccination is recommended. Although several tuberculosis vaccine candidates are under clinical development, none have replaced BCG in national immunization programs or routine public health practice.

The level of geographical expansion is moderate as manufacturers continue to strengthen vaccine supply in countries with a moderate to high tuberculosis burden. Demand is supported by national immunization programs across Asia Pacific, Africa, and parts of Latin America. Companies are also investing in manufacturing capacity and working with public health agencies to improve vaccine availability in underserved regions.

Analyst Perspective

The BCG vaccine industry is supported by its continued use in tuberculosis prevention and the treatment of non-muscle invasive bladder cancer. Routine childhood immunization programs provide stable demand across many countries. Market performance depends on production capacity, product availability, and compliance with quality standards. Ongoing research may support additional clinical applications of BCG in cancer treatment. Manufacturers that maintain a reliable supply, improve production efficiency, and meet regulatory requirements are expected to strengthen their position in the market.

Product Insights

The immune BCG vaccine segment accounted for the largest market share of 75.3% in 2025. The segment dominates the market because it is included in routine childhood immunization programs across many countries with a moderate to high tuberculosis burden. Government procurement through national immunization programs ensures consistent demand and supports large-scale vaccine distribution. Recommendations from the World Health Organization and national health authorities continue to strengthen their adoption in public vaccination schedules. The vaccine is administered shortly after birth in many countries, resulting in stable procurement volumes every year. Its established safety profile, long history of clinical use, and widespread availability through public healthcare systems further support demand.

The therapeutic BCG vaccine segment is projected to register the fastest CAGR of 8.5% during the forecast period. Growth is driven by the increasing use of BCG in the treatment of non-muscle invasive bladder cancer and the rising number of patients requiring intravesical therapy. Continued adoption by hospitals and urology centers supports demand, while ongoing clinical research is evaluating BCG in combination with newer immunotherapies to improve treatment outcomes. Increasing awareness of early bladder cancer diagnosis, expanding access to specialized cancer care, and growing investment in oncology services are also contributing to segment growth. In addition, manufacturers are focusing on improving product availability to address supply challenges and meet clinical demand.

Distribution Channel Insights

The public sector accounted for the largest share of 77.9% in 2025. The segment dominates because BCG vaccination is primarily delivered through government-funded immunization programs in countries with a moderate to high tuberculosis burden. National health authorities procure vaccines in large volumes to support routine childhood vaccination, ensuring stable demand. Support from international organizations such as UNICEF and Gavi further strengthens vaccine procurement and distribution in low- and middle-income countries. Public healthcare facilities provide broad access to newborn vaccination, while centralized procurement helps maintain consistent vaccine availability. In addition, government investments in tuberculosis control programs and established public health infrastructure continue to support large-scale vaccine administration.

To learn more about this report, Download Free Sample Report

The private sector is projected to register the fastest CAGR of 10.0% during the forecast period. Growth is supported by the increasing role of private hospitals, specialty clinics, and diagnostic centers in providing vaccination and bladder cancer treatment services. Rising healthcare spending, expansion of private healthcare infrastructure, and greater access to specialized medical services are contributing to segment growth. In several countries, individuals are also choosing private healthcare facilities because of shorter waiting times and broader access to medical specialists. The growing use of BCG for the treatment of non-muscle invasive bladder cancer in private hospitals is further supporting demand. In addition, continued investment in private healthcare networks and expanding oncology services are expected to strengthen the role of the private sector, resulting in faster growth during the forecast period.

Regional Insights

The BCG vaccine market in Asia Pacific accounted for the largest share of 47.8% in 2025. The region has a large birth population, resulting in sustained demand for BCG vaccines through routine childhood immunization programs. A higher tuberculosis burden across several countries continues to support widespread BCG vaccination during infancy. The presence of leading vaccine manufacturers and established production facilities contributes to consistent product availability across the region. Increasing healthcare access and improving vaccination coverage continue to strengthen vaccine demand in both urban and rural areas.

To learn more about this report, Download Free Sample Report

Japan BCG Vaccine Market Trends

The Japan BCG vaccine market is supported by routine childhood BCG vaccination and an established vaccine manufacturing industry. The country maintains consistent demand through regular infant immunization practices and a well-developed healthcare system. Domestic manufacturers continue to focus on maintaining production quality and a stable vaccine supply. The use of BCG in bladder cancer treatment also supports demand from hospitals and specialized urology centers. Continuous improvements in healthcare services and patient access contribute to stable product utilization.

The BCG vaccine market in China represents a significant market due to its large infant population and continued focus on tuberculosis prevention. Routine childhood vaccination creates a steady demand for BCG vaccines across the country. The presence of domestic vaccine manufacturers supports local production and product availability. Expanding healthcare infrastructure has improved access to vaccination and specialized medical services in many regions. The increasing diagnosis of bladder cancer is also supporting the use of therapeutic BCG in hospitals.

North America BCG Vaccine Market Trends

The North America BCG vaccine market is projected to register the fastest growth of 6.4% during the forecast period. Growth is supported by the increasing use of BCG in the treatment of non-muscle invasive bladder cancer across hospitals and specialized cancer centers. Rising bladder cancer incidence continues to increase the demand for intravesical BCG therapy in clinical practice. Ongoing clinical research evaluating BCG in combination with immunotherapies is expanding treatment options for eligible patients. Healthcare providers are strengthening access to specialized urology and oncology services, supporting higher treatment volumes. Continued efforts by manufacturers to improve product availability are further contributing to market growth across the region.

The BCG vaccine market in the U.S. is primarily driven by the established use of BCG as a standard treatment for non-muscle invasive bladder cancer in hospitals and cancer centers. A large patient population requiring bladder cancer treatment supports consistent product demand. The presence of advanced healthcare infrastructure enables wider access to specialized urology services and follow-up care. Continuous clinical research involving BCG-based treatment approaches is contributing to broader clinical adoption. Investments in oncology care and increasing awareness of early cancer diagnosis continue to support market expansion in the country.

Europe BCG Vaccine Market Trends

The BCG vaccine market in Europe is supported by routine tuberculosis vaccination in selected countries and the continued use of BCG for bladder cancer treatment. Demand remains stable through established healthcare systems and clinical practice guidelines for eligible patients. The presence of experienced vaccine manufacturers and contract manufacturing organizations supports product availability across the region. Healthcare providers continue to expand access to specialized oncology and urology services, increasing treatment volumes. Research institutions are actively evaluating BCG in cancer immunotherapy, contributing to scientific development. These factors continue to support the regional market across both infectious disease prevention and oncology applications.

The UK BCG vaccine market is supported by targeted tuberculosis vaccination programs for high-risk populations and continued clinical use in bladder cancer treatment. Healthcare providers follow established clinical guidelines for intravesical BCG therapy in eligible patients with non-muscle invasive bladder cancer. The country's developed oncology infrastructure supports access to specialized diagnosis, treatment, and follow-up services. Research organizations continue to evaluate new treatment combinations involving BCG for bladder cancer management. Strong collaboration between hospitals and academic institutions supports clinical research activities. These factors contribute to steady demand for BCG vaccines across preventive and therapeutic applications.

The BCG vaccine market in Germany is driven by an established healthcare infrastructure and extensive oncology services. Demand is supported by the continued use of BCG as a standard treatment for non-muscle invasive bladder cancer in hospitals and specialized urology centers. The presence of experienced healthcare professionals enables consistent adoption of guideline-based treatment. Clinical research activities focusing on immunotherapy combinations continue to increase scientific interest in BCG-based therapies. Strong diagnostic capabilities support early identification of bladder cancer patients requiring treatment.

The France BCG vaccine market is supported by the continued use of BCG in the treatment of non-muscle invasive bladder cancer and the country's established clinical oncology network. Hospitals and specialized urology centers continue to use intravesical BCG as a standard treatment for eligible patients. Rising awareness of early bladder cancer diagnosis is increasing the number of patients receiving timely treatment. The presence of experienced healthcare professionals supports the consistent use of guideline-based therapies. Ongoing clinical studies related to cancer immunotherapy continue to strengthen the role of BCG in oncology. These factors contribute to stable demand for BCG vaccines across therapeutic applications in France.

Latin America BCG Vaccine Market Trends

The BCG vaccine market in Latin America is supported by the continued use of BCG in routine childhood vaccination and increasing attention to tuberculosis prevention. Many healthcare providers continue to administer the vaccine at birth, resulting in stable annual demand. Expanding healthcare infrastructure has improved access to vaccination services across several parts of the region. The growing availability of diagnostic services is supporting earlier detection and treatment of bladder cancer, increasing the use of therapeutic BCG. Regional manufacturers and international suppliers continue to maintain vaccine availability through established distribution networks.

Brazil BCG vaccine market is driven by its large birth population and continued use of BCG in routine infant vaccination. Consistent demand for tuberculosis prevention supports stable vaccine procurement across healthcare facilities. The country also has an established clinical practice for using BCG in the treatment of non-muscle invasive bladder cancer. Improvements in healthcare access have increased the availability of vaccination and specialized oncology services. Growing awareness of early disease diagnosis is supporting timely treatment and patient management.

Middle East & Africa BCG Vaccine Market Trends

The BCG vaccine market in the Middle East & Africa is supported by the continued need for tuberculosis prevention across several countries with moderate to high disease burden. Routine infant vaccination remains an important contributor to vaccine demand throughout the region. Improvements in healthcare infrastructure are increasing access to immunization services and strengthening vaccine coverage. The expansion of hospital networks and specialized medical facilities is also supporting the use of BCG in bladder cancer treatment. Manufacturers continue to improve product availability through regional supply partnerships and distribution channels.

The Saudi Arabia BCG vaccine market is supported by routine newborn vaccination and the country's expanding healthcare infrastructure. Healthcare providers continue to administer BCG as part of standard infant immunization practices, supporting consistent vaccine demand. The presence of advanced hospitals and specialized oncology centers has increased the use of BCG for non-muscle invasive bladder cancer treatment. Greater access to diagnostic services is contributing to earlier disease detection and improved patient management. Ongoing investments in hospital capacity and specialized medical services continue to strengthen vaccine utilization across preventive and therapeutic applications.

Key BCG Vaccine Company Insights

The BCG vaccine market is moderately concentrated, with a limited number of manufacturers supplying vaccines for tuberculosis prevention and bladder cancer treatment. Competition is based on manufacturing capacity, product quality, regulatory compliance, supply reliability, and participation in public procurement programs. Companies are focused on maintaining consistent production, expanding manufacturing capabilities, and meeting international quality standards to strengthen their market position. Public-sector vaccine institutes and regional manufacturers play an important role in supplying domestic and international markets, while established pharmaceutical companies continue to support oncology applications of BCG. Long-term supply agreements established distribution networks, and compliance with global regulatory requirements remain important factor for maintaining competitiveness.

Key BCG Vaccine Companies

The following key companies have been profiled for this study on the BCG vaccine market.

• Merck & Co., Inc.

• Serum Institute of India Pvt. Ltd.

• Japan BCG Laboratory

• AJ Vaccines A/S

• China National Biotec Group (CNBG)

• GreenSignal Bio Pharma Ltd.

• InterVax Ltd.

• BioFarma

• Biomed-Lublin S.A.

• BB-NCIPD Ltd.

Recent Developments

• In July 2026, Serum Institute of India Pvt. Ltd. partnered with Gates Medical Research Institute to manufacture the investigational M72/AS01E tuberculosis vaccine and expand future TB vaccine manufacturing capacity.

• In May 2026, Japan BCG Laboratory entered into an exclusive development and supply agreement with ImmunityBio to manufacture and supply the Tokyo-172 strain of BCG for development and commercialization in the U.S. for bladder cancer treatment.

Global BCG Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global BCG vaccine market report based on product, distribution channel, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Immune BCG Vaccine

  • Therapeutic BCG Vaccine

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Public Sector

  • Private Sector

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The BCG vaccine market was estimated using a commodity flow and revenue-based approach. The study identified key manufacturers producing BCG vaccines for tuberculosis immunization and bladder cancer treatment and benchmarked their product portfolios, manufacturing capacity, pricing, geographic presence, and distribution channels. Revenue generated from key BCG vaccine products was assessed using company annual reports, regulatory filings, investor presentations, procurement records, government immunization data, UNICEF and PAHO supply information, and public health publications. Product-level revenues were aggregated to estimate the existing market and validated by analyzing procurement volumes, vaccination coverage, bladder cancer treatment demand, manufacturing output, and regional supply trends. Market estimates were further verified through primary interviews with vaccine manufacturers, distributors, healthcare professionals, procurement agencies, and industry experts. Data triangulation and regional validation were applied to produce consistent market size estimates across major countries and regions.

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations